The amyloid deposits of Alzheimer's disease contain, in addition to the p protein (Ap), lesser amounts of other proteins including the protease inhibitor m-antichymotrypsin (ACT). We have recently shown that ACT acts as a pathological chaperone, binding to the I~ protein and strongly promoting its polymerization into amyloid filaments in vitro. The data of this paper show that ACT synthesis is induced in cultured human astrocytes by IL-1, a lymphokine whose expression is strongly up-regulated in microglial cells in affected areas of AIzheimer's disease brain. Furthermore, unfractionated glial Cultures containing both astrocytes and microglia from human cortex (which develops amyloid in Alzheimer's disease) spontaneously express IL-1 and ACT as they reach confluence. In contrast, confluent mixed glial cultures similarly prepared from human cerebellum or brain stem, or from rat braintissues not prone to amyloid formation-do not express ACT unless supplemented with exogenous IL-1. The same regional difference in IL-1 expression by mi. croglia is seen in vivo in Alzheimer's disease. These results indicate that the IL-l-induced expression of ACT may help direct the region-specific production of mature amyloid filaments in the Alzheimer brain.
Introduction
The earliest detectable lesions in the brains of Alzheimer's disease patients (and Down syndrome patients, all of whom also show Alzheimer neuropathology by age 30-40) are amorphous, pre-amyloid deposits of 13 protein (Wisniewski and Terry, 1973; Mann et al., 1985; Probst et al., 1987; Giaccone et al., 1989; Ikeda et al., 1989) . The Alzheimer 13 protein (Aj3) is an approximately 40 amino acid peptide that is derived by proteolytic processing from a larger amyloid precursor protein, I~APP (Glenner and Wong, 1984; Masters et al., 1985; Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 1987) . As the disease progresses, the mature Alzheimer amyloid arises, forming the cores of the neuritic plaques found predominantly in higher centers of the brain and accumulating in the walls of the cerebral and meningeal vasculature (Glenner, 1980; Selkoe, 1991) . Using electron microscopy, Alzheimer amyloid deposits can be seen to consist of large meshworks of protein filaments approximately 7 nm wide (Merz et al., 1983) . The amyloid maturation process in Alzheimer's disease and Down syndrome presumably reflects either a conversion from the amorphous to the filamentous form of deposit or an independent assembly of the amyloid filaments.
There are several puzzling features of the filamentous amyloid deposits of Alzheimer's disease and Down syndrome brains. First, their deposition shows a striking regional specificity. Amorphous, pre-amyloid deposits of AJ3 can be found in many brain regions, including the neocortex, hippocampus, and amygdala, as well as the cerebellum and brain stem (Yamaguchi et al., 1988; Joachim et al., 1989a) . However, the mature, filamentous deposits arise only in certain areas, such as the neocortex, hippocampus, and amygdala, and in the walls of cerebral and meningeal blood vessels. The second unusual feature of Alzheimer amyloid is the presence of other structural components besides the AI3 peptide. For instance, the protease inhibitor ~l-antichymotrypsin (ACT) is intimately associated with the AI3 protein filaments in the mature amyloid of Alzheimer's disease, but is not present in the amyloid deposits of other diseases (Abraham et al., 1988 (Abraham et al., , 1990 . Interestingly, the amorphous AI3 deposits in nonaffected areas of Alzheimer brain such as the cerebellum are largely devoid of ACT (Abraham et al., 1988; Rozemuller et al., 1990 Rozemuller et al., , 1991 , although some ACT staining of cerebellar plaques has been found by Shoji et al. (1991) . Other components of Alzheimer and other amyloid include apolipoprotein E (apoE), heparan sulfate proteoglycan (HSPG), and several complement proteins (Eikelenboom, 1989; Snow et al., 1989; Namba et al., 1991; Wisniewski and Frangione, 1992) .
The presence of some associated proteins in Alzheimer amyloid may be due to adventitious adhesion. However, the strong, specific affinity of ACT, apoE, and HSPG for the A~ peptide in vivo and in vitro suggests that these proteins might participate directly in amyloid deposition by serving as pathological chaperones for the AI3 peptide (Abraham et al., 1988; Potter et al., 1991; Snow et al., 1988 Snow et al., , 1989 Snow et al., , 1994 Wisniewski and Frangione, 1992; Strittmatter et al., 1993; Wisniewski et al., 1993) . Furthermore, the areas of Alzheimer brain in which mature amyloid deposits accumulate are distinguished by greatly enhanced levels of ACT mRNA and soluble protein (Abraham et al., 1988 (Abraham et al., , 1990 . We recently examined the influence of ACT and another putative pathological chaperone, apoE, on the spontaneous polymerization of AI3 into amyIoid filaments in vitro and found that these proteins strongly promoted filament formation (Ma et al., 1994 ; see also Wisniewski et al., 1994; Sanan et al., 199,$) . Together, these results suggest that amyloid formation in Alzheimer's disease brain may reflect the availability not only of the AI3 peptide itself but of amyloid-promoting factors such as ACT, apoE, or HSPG. Thus, the expression of these proteins in the brain may be a critical step in the development of mature Alzheimer neuropathology. IIn this paper, we investigate the mechanism by which ACT, the patho-logical chaperone most specific for Alzheimer amyloid, is overexpressed in affected areas of the Alzheimer brain.
Unlike the AI~ protein, which is believed to be produced primarily by endogenous brain neurons (Card et al., 1988; Higgins et al., 1988; Palmert et al., 1988; Benowitz et al., 1989 ; but see also Joachim et al., 1989b) , ACT is derived from gila. In situ hybridization with ACT cRNA probes, coupled with ACT and glial fibrillary acidic protein (GFAP) immunostaining, demonstrate that the increased ACT expression in Alzheimer brain occurs in astrocytes surrounding the amyloid deposits (Pasternack et al., 1989; Abraham et al., 1990; Koo et al., 1991) . The increased immunostaining of these cells for GFAP further indicates that the ACT-expressing astrocytes have become reactive in response to a local inflammatory insult and associated signaling molecule(s).
A hint as to how expression of ACT might be induced in astrocytes comes from the fact that, normally, this protease inhibitor is produced in the liver as part of the body's response to inflammation. Specifically, certain lymphokines, in particular interleukin-1 (IL-1), can induce ACT expression in hepatocytes both in vivo and in vitro (Baumann et al., 1987) . We therefore investigated the ability of glial cells from different areas of human brain to express ACT in response to IL-1. The results of these and other experiments suggest that a region-specific, acute phaselike response in the brain, very similar to that seen in the liver, is a necessary link in the chain of events that leads first to the formation of mature amyloid deposits and ultimately to neuronal cell death and dementia. (Bauman net al., 1987) have indicated that the lymphokines IL-1 and IL-6 and the glucocorticoid dexamethasone are among the signal molecules that induce hepatocytes in the liver to begin overexpressing ACT during the peripheral acute phase response. It is perhaps significant that these acute phase-inducing agents are present in higher amounts in the brains of Alzheimer's disease patients compared with age-matched control individuals. IL-1 immunoreactivity is present in 6-fold as many cortical microglial cells in Alzheimer's disease patients compared with controls (Griffin et al., 1989 ; see also Cacabelos et al., 1994; Sheng et al., 1994) , and IL-1 appears to cause the astrogliosis that follows brain injury (Giulian and Lachman, 1985) . In addition, there is an increase in plasma cortisol and in corticotropin-releasing factor in cerebral spinal fluid in Alzheimer's disease patients (Davis et al., 1986; Martignoni et al., 1990) . We therefore tested directly the ability of these agents to induce expression of the acute phase protein ACT in human astrocytes grown in vitro.
Results

Experiments in vitro
Establishment of Primary Glial Cultures from Human and Rat Brain
As described in Experimental Procedures, brain tissue was disaggregated, and the cells were placed in primary culture. After 1-2 weeks, the majority of neurons had died and detached from the substrate, leaving a confluent monolayer of glial cells. The morphology of the cells indi- Figure 1 . Immunocytochemistry of Human Mixed Glial Cells in Primary Culture Cultures were prepared as described in Experimental Procedures and grown to confluence in fetal calf serum-containing DMEM medium. Immunolabeling with a monoclonal antibody against GFAP (A) demonstrates that 85%-90% of the cells stain for this astrocyte-specific protein, while the control (B), using normal goat serum in place of the primary antibody, shows only a low background staining. Immunolabeling with anti-ACT serum (C) indicates that most astrocytes grown to confluence in serumcontaining medium express this acute phase protein. In (D), the primary anti-ACT serum was replaced with normal serum as a control.
D
cated that most were astrocytes, together with a few microglia. This conclusion was confirmed by immunolabeling the cells with an antibody to the astrocyte-specific protein GFAP, which identified 85%-90% of the cells as astrocytes (Figure 1) .
Although ACT is overexpressed in astrocytes in areas of Alzheimer's disease brain exhibiting pathology (Abraham et al., 1988) , the level of ACT mRNA and protein in normal age-matched control brain is undetectable (Abraham et al., 1988 ; see also Esiri and Booss, 1984; Justice et al., 1987) . Following their removal from the animal and initial culturing in serum-containing medium, however, astrocytes begin to express a high level of ACT mRNA and protein (Figure 1 ). The normal, low level of ACT expression is reestablished by exposing the cells to serumfree medium for 2 hr.
IL-1 Induces ACT Expression in Cultured Human Astrocytes
As discussed above, IL-1, together with glucocorticoids, has been shown to be an effective inducer of ACT expression in hepatocytes, and the level of these agents has been found to be elevated in AIzheimer's disease brain. We therefore tested the ability of I!_-1 and the glucocortix c, c~ (A) Mixed glial cultures from human fetal frontal cortex were prepared as described in Experimental Procedures, grown to subconfluence in serum-containing medium, then switched to serum-free N2 medium for 2 hr. The cultures were then treated with IL-le (250 U/ml) and/or dexamethasone (1 #M) for 4 hr, at which time RNA was isolated and subjected to Northern blot analysis with an ACT probe. IL-1 alone was able to induce ACT expression in cortical cultures. There is a small synergistic effect of adding dexamethasone together with IL-I. (B) Cultures similarly prepared from cerebellum and brain stem showed a similar response to IL-1 and dexamethasone, as did the cortical cultures.
coid agonist dexamethasone to induce the expression of ACT in cultures of human fetal glial cells growing in defined medium. We also determined whether mixed glial cultures from different brain regions exhibit differential sensitivity to these factors. As shown in Figure 2A , addition of human recombinant IL-la (250 U/ml) induced an increase in the amount of ACT messenger RNA in subconfluent mixed glial cells from the frontal cortex. Most of this response could be elicited by IL-1 alone. There was a small synergistic effect of the further addition of dexamethasone (1 #M) on the level of ACT mRNA. Cerebellum and brain stem cultures also exhibited an increase in the amount of ACT mRNA when treated with dexamethasone and IL-1 ( Figure 2B ). The induction was similar to, or somewhat lower than, that seen in the cortical subconfluent cultures (Table 1) . Previous in situ hybridization and GFAP immunocytochemistry on Alzheimer brain sections showed that large numbers of reactive astrocytes expressing ACT surround mature amyloid plaques (Abraham et al., 1988; Pasternack et al., 1989; Koo et al., 1991) . The ACT and GFAP immunocytochemistry of mixed glial cultures grown to confluence in serum-containing medium also indicated that the astrocytes were the primary cells capable of expressing ACT in vitro ( Figure 1 ). To confirm further that astrocytes were indeed the cells in which IL-1 induced an increase in ACT mRNA levels in mixed glial cultures, we removed the major contaminating cell-type microglial cells. Three procedures were employed. First, we developed a procedure of light trypsinization, followed by the discard of the nonadherent cells (including microglia) and the retention of the adherent astrocytes. Second, the method of Lee et al. (1992) consists of vigorously shaking mixed glial cultures and removing the microglial cells that are released into the culture medium. Finally, H-Leu-OMethyl Ester hydrochloride is specifically toxic to microg- Northern blot analysis and total cellular RNA from various brain regions was hybridized to an ACT probe, as described. Following autoradiography, the relative strengths of the bands in the samples from cells with and without addition of IL-1 and dexamethasone were determined by densitometer analysis. As discussed in the text, cortical cultures spontaneously express ACT when they reach confluence and are then no longer responsive to the addition of exogenous IL-1. To confirm that the increase in ACT mRNA induced by IL-1 and dexamethasone occurred in the astrocytes in the mixed glial cultures, we removed the microglial cells from subconfluent mixed cortical glial cultures and treated the remaining purified astrocyte cultures with IL-1 and dexamethasone. Three treatments were employed to remove microglial cells, as described in Experimental Procedures: by light trypsin digestion and the removal of the nonadherent cells, by vigorous shaking to remove nonadherent cells, and by trea:tment with 5 mM H-Leu-O-Methyl ester. The removal of the microglial cells by any of these three procedures had no effect on the induction of ACT mRNA by IL-1 and dexamethasone.
lial cells (Giulian, 1987) . Each of these three procedures was used to generate pure astrocyte cultures from the subconfluent pri mary mixed glial cultures. The relative absence of the nonadherent microglial cells was confirmed by microscopic examination of cell morphology. All brain regions yielded similar proportions of purified astrocytes and microglia. The mixed culture and the different preparations of purified astrocytes were immediately exposed to IL-1 and dexamethasone. The level of ACT mRNA was determined by Northern blot analysis and found to be increased to the same extent (Figure 3) , indicating that the IL-l-sensitive cells are indeed the astrocytes. These results indicate that, like hepatocytes, astrocytes from the various areas of human fetal brain can respond to IL-1 and dexamethasone by increasing the expression of the acute phase protein ACT. Both areas prone to AIzheimer's pathology, such as the cortex, and areas not so prone, such as the cerebellum, show similar responses to these inducing agents.
Confluent Glial Cultures from Human Cortex, but Not Cerebellum or Brainstem, Spontaneously Express ACT as They Reach Confluence
A lower baseline level of ACT messenger RNA was often seen in cultures derived from the cerebellum or brain stem as compared with the cortex. This observation indicated a potential difference in the ability of mixed glial cultures from different brain regions to initiate spontaneously an acute phase response and induced us to examine further the endogenous ACT expression under various conditions. Mixed glial cultures derived from human fetal cortex, cerebellum, and brain stem were allowed to grow to confluence and then analyzed for the level of ACT mRNA. The results shown in Figure 4A and Table 1 Cultures of mixed glial cells were prepared as described in Experimental Procedures from human frontal cortex, cerebellum, and brain stem, grown in serum-containing medium to approximately 80% confluence. The cultures were then switched to N2 medium and allowed to reach confluence over the ensuing 12 hr. RNA was prepared and subjected to Northern blot analysis using an ACT probe.
(A) Cultures prepared from the frontal cortex spontaneously expressed a high level of ACT mRNA, which could not be further induced by the addition of IL-1 and dexamethaeone. In contrast, the cultures prepared from the brain stern or cerebellum at various times after they reached confluence continued to express the low level of ACT m R NA of subconfluent cultures and were still sensitive to induction by IL-1 and dexamethasone.
(B) Human cortical mixed glial cultures allowed to reach confluence either in the absence or presence of 2.5 I~g/ml blocking antibody to the I L-1 receptor.. Northern blot analysis of equal amounts of total RNA isolated from the two cultures indicated that the spontaneous level of ACT mRNA was greatly reduced in the presence of the antibody.
from the addition of dexamethasone and/or IL-1. In contrast, confluent cultures of mixed glia derived from the cerebellum or the brain stem did not express ACT mRNA, despite the fact that they contained the same number of astrocytes as the cortical cultures. Furthermore, they contained the same number of microglia, as indicated by the fact that there was no significant difference in the number of microglia recovered from the various confluent cultures by vigorous overnight shaking (as assayed by staining with two macrophage/microglial cell-specific antibodies). The confluent cerebellar and confluent brain stem cultures can, however, be induced to express ACT by the addition of IL-1 and dexamethasone, just as can the subconfluent cultures from these brain regions shown in Figure 2 . It therefore seemed likely that IL-1 is the inducing agent that is uniquely generated in the confluent cortical cultures and stimulates the endogenous astrocytes to express ACT. To test this hypothesis, a subconfluent mixed glial culture from human frontal cortex was supplemented with an antibody that noncompetitively blocks IL-1 receptor function, and the cells were then allowed to grow to confluence. In comparison with an identical, untreated culture, there was a substantial reduction in the spontaneous expression of ACT mRNA in the presence of the blocking antibody (Figure 4B) . Because microglial cells are the primary source of IL-1 in the brain and because purified astrocytes fail to express ACT when they reach confluence, it seems most likely that the differences in the cultures from different brain regions reflect differences in the microglial population. Because no significant differences in the numberof microglial cells recovered from the confluent cortical and cerebellar cultures were observed the difference in astrocyte activation likely resides in the ability of the microglial cells to synthesize and/or secrete IL-I.
Microglial Cells Differ in Different Areas of Alzheimeds Disease Brain
Because the in vitro experiments suggested that microglial cells derived from different parts of the brain might differ in their ability to synthesize or secrete IL-1, we analyzed sections of human Alzheimer and control brain for the presence of IL-l-expressing microglial cells. Griffin et al. (1989) had previously shown that Alzheimer brain cortex contains many-fold higher numbers of IL-l-positive gtial cells than normal cortex. As shown in Table 2 , we have confirmed this result and have further found that IL-1-positive microglial cells are not increased to the same extent in the cerebellum of Alzheimer brain. A similar conclusion has recently been reached by Cacabelos et al. (1994) and Sheng et al. (1994) , who studied total IL-1 levels in various brain regions.
In summary, the cerebellum not only fails to support mature amyloid deposition in Alzheimer's disease, but the in vitro studies also show that the cerebellar cultures are not prone to the production of IL-1 by microglial cells and the consequent expression of the amyloid-promoting factor ACT. Thus, both in vitro and in vivo studies indicate that microglial production of IL-1 is aberrant in Alzheimer's disease, being increased only in those areas prone to amy- Microglial cells were identified in paraffin-fixed sections by immunohistochemistry for I L-1, as described, and the number of cells determined for fifty 40 x microscope fields (a total of 3.5 mm 2) in the sections from cortex or cerebellum of Alzheimer's or age-matched control individuals, as indicated.
Ioid pathology. The in vitro studies further suggest that the defect is intrinsic to the microglial cells, but it is also possible that an unidentified signaling molecule or lymphokine is released only in cortical areas of the brain and primes the local microglial cells to produce IL-1 when they are cultured in vitro.
IL-1 Fails to Induce ACT Expression in Rat Brain Astrocytes
Although A~-and ACT-containing amyloid deposits are present in small numbers in the brains of most aged primates, similar pathology has not been found in rodents (Wisniewski and Terry, 1973; Struble et al., 1985; Selkoe et al., 1987; Ab~'aham et al., 1989) . Indeed, attempts to develop an animal model of Alzheimer's amyloid formation by generating transgenic mice that overexpress human 13APP have been somewhat disappointing (e.g., Quon et al., 1991; Wirak et al., 1991) . One possible explanation for these results is that the rodent brain may not be a fertile environment for A~ deposition, perhaps owing to a difference in the glial population. Certainly the relative number of glia compared with neurons is many-fold higher in humans.
We have found that, in contrast to its clear role in initiating the liver acute phase response and its ability to induce ACT expression in human astrocytes in culture (shown in Figure 2 and Figure 3 ), I1_-1 fails to increase ACT (contrapsin) mRNA in astrocyte-rich mixed glial cultures from rat brain ( Figure 5, compare lanes 1 and 2) . Another lymphokine, IL-6 (believed to be the immediate acute phase-inducing signal in v ivo [Baumann et al., 1989] ) is also able to induce ACT expression in hepatocytes in the presence of dexamethasone. However, neither IL-6 alone nor IL-6 in combination with IL-1 induces increased levels of ACT mRNA in rat brain gila. Several other proteins, such as transforming growth factor 13 and epidermal growth factor, which have previously been shown to mediate the glial response to injury (Nieto-Sampedro, 1988; Birecree et al., 1988) , have also been tested and found incapable of inducing ACT expression in the cultured rat brain gila (data not shown). a n __.
n " r r r r n " or" O2 n "
Figure 5. Effect of Various Acute Phase Mediators on the Expression of Contrapsin/ACT in Rat Cultures
Mixed glial cultures were grown to confluence in 10% serumcontaining medium and then switched to N2 defined medium. The cells were then treated for 6 hr with no treatment (1), 250 U/ml IL-1 (2), 1 ~M dexamethasone (3), 250 U/ml IL-1 + 1 p_M dexamethasone (4), 250 U/ml IL-6 (5), 250 U/ml IL-6 + 1 p.M dexamethasone (6), and 250 U/ml IL-1 + 250 U/ml IL-6 (7). Total RNA was isolated from the cultures and subjected to Northern blot analysis using the contrapsin cDNA probe. The data show that the amount of ACT/contrapsin mRNA is greatly increased by treatment with dexamethasone alone, but not with IL-1 or IL-6.
Dexamethasone Induces Expression of ACT in Cultured Rat Astrocytes
Since dexamethasone is an important coregulator of ACT expression in rat hepatocytes during the peripheral acute phase response, but is without effect by itself, we tested the effect of this signal molecule on the rat brain mixed glial cultures. As shown in Figure 5 (lanes 1 and 3) , treatment of quiescent cultures in serum-free medium with 1 ~M dexamethasone alone for 6 hr induced ACT mRNA 20-to 30-fold. Neither IL-1 nor IL-6 acted synergistically to increase the ACT induction by dexamethasone. In summary, rat and human glia exhibit very different abilities to express the amyloid-promoting factor ACT. Human astrocytes are sensitive to IL-1, with a slight synergistic effect with dexamethasone, whereas the rat astrocytes are insensitive to IL-1 and instead show a striking response to dexamethasone. Even when allowed to reach confluence, rat glial cultures still fail to express ACT, in contrast to the human cultures, which spontaneously express ACT if isolated from brain areas that are prone to developing Alzheimer's disease pathology. Together, these results suggest that the ability of a brain region--human or rat--to express the acute phase protein ACT in vitro correlates with its ability in vivo to express mature Alzheimer amyloid pathology and reflects the presence of microglial cells able to synthesize and release the ACT-inducing lymphocine IL-1.
Discussion
It is becoming increasingly clear that the human degenerative brain disorder called Alzheimer's disease results from a complex pathogenic pathway whose steps beyond the production of the AI5 protein are only beginning to be delineated. For instance, the association of the acute phase protein ACT with amyloid neuropathology first suggested the possibility that a brain acute phase response played a role in the conversion of amorphous AI3 deposits to mature amyloid (Abraham et al., 1988; Rozemuller et al., 1990; Potter et al., 1991) . The more recent findings that ACT binds tightly to AI3 peptide and is a strong amyloid-promoting factor, stimulating the polymerization of AI3 into amyloid filaments in vitro, provide one mechanism by which ACT overexpression in certain regions of the Alzheimer brain could contribute to amyloid deposition in vivo Potter, 1992; Ma et al., 1994) . Other pathological chaperones may be similarly involved in amyloid production. Certainly, the fact that AI3 is a normal constituent of body fluids and is released by all 13APP-expressing cells (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992) indicates that the formation of mature amyloid deposits cannot depend on AI3 production alone. Instead, the turning point in the development of Alzheimer neu ropathology may be the disease-and tissuespecific production of pathological chaperones that direct when and where amyloid will form in the affected individual.
The data of this paper support this model in several ways and suggest additional steps in the pathogenic pathway in Alzheimer's disease. First, they show that the expression of the most Alzheimer-specific pathological chaperone, ACT, is induced in human astrocytes by IL-1, a known acute phase-inducing agent that is overexpressed in AIzheimer cortex. Moreover, different brain regions show different capabilities for spontaneously expressing an acute phase reaction in vitro, with the same regional specificity with which the expression of acute phase proteins and the formation of filamentous amyloid occur in Alzheimer's disease. Finally, rat brain astrocytes differ from those of humans in failing to express acute phase proteins in response to IL-I. Thus, the normal inability of aged rodents to exhibit classic Alzheime~ike neuropathology may result both from differences in the AI3 sequence, with the rodent sequence being possibly less prone to polYmerization, and from the lack of appropriate pathological chaperones. Sufficient overexpression of a human APP gene carrying a familial Alzheimer's disease mutation may circumvent these deficits and lead to AI3 amyloid formation in transgenic mice.
What might initiate the inflammatory/acute phase cascade? The earliest pathological change that can be found in Alzheimer's disease brain--the accumulation of amor-phous deposits of AI3 protein--is the most likely candidate. If such AI3 protein deposition occurs in an area such as the cerebellum, which does not appear capable of expressing an inflammatory reaction or acute phase response, its pathological effect is evidently minor. The deposit remains amorphous, and there is no glial involvement and no resulting neuronal degeneration. However, in the gray matter of the cerebrum, especially in the hippocampus, amygdala, and neocortical regions, AJ3 production and amorphous aggregation may induce the observed microglial cell activation, division, and increased release of IL-1, which can then activate adjacent astrocytes. Indeed, AI3 appears to have just such an activating effect on rat microglia in vitro (Araujo and Cotman, 1992) . The resulting astrocyte-led acute phase response would then produce the pathological chaperone ACT and other components of mature amyloid including, potentially, apoE. A number of proteases, such as clipsin (Nelson and Siman, 1990; Nelson et al., 1993) and some cathepsins (Cataldo and Nixon, 1990) , are likely to be released during the inflammation and subsequent acute phase response and may increase the cleavage of AI3 from its precursor. I~APP expression itself is increased in reactive astrocytes induced by injury (Siman etal., 1989; Otsuka et al., 1991) and in endothelial, neuronal, and glial cells exposed to IL-1 (Goldgaber etal., 1989; Forloni et al., 1992) . Thus, an accelerating cycle of AI3 production and maturation into amyloid filaments can be established in areas of the brain in which glial cells can be recruited to participate in the pathology. Indeed, the two key cell types in this model, activated microglia and reactive astrocytes, are found within and surrounding the amyloid plaques in Alzheimer brain (Duffy etal., 1980; Itagaki etal., 1989; Pasternack etal., 1989; Abraham etal., 1990; Koo etal., 1991 ; McGeer etal., 1993) . Ultimately, neuronal cell death occurs, perhaps as a direct consequence of toxicity of AI3 or AI3 filaments (Yankner et al., 1989 (Yankner et al., , 1990 .
In summary, Alzheimer pathology and neuronal degeneration may result from a complex pathogenic pathway in which initial widespread, amorphous AI3 protein deposition is followed in specific brain regions by a reaction of astrocytes and microglia to the deposits. Together, these lead to the production and release of ACT and other pathological chaperones and to the development of mature, filamentous amyloid. Thus, AIzheimer's disease may be an example of a disorder in which the organism's response to an initial insult makes an essential contribution to the final pathology.
Experimental Procedures Preparation of Astrocyte Cultures
Mixed glial cultures were prepared from portions of human brain and from whole brains of day 1 postnatal rats from which the meninges and mid and hind brain had been removed. Tissue samples from anatomically normal, intact human fetuses were retrieved after elective pregnancy termination with signed consent of the mother and in accordance with formal procedures and guidelines and of the Brigham and Women's Hospital Human Research Committee. All fetuses were approximately 18-20 weeks gestational age, as determined by measurements of crown-rump length, foot length, and weight. The brains were removed within 2 hr of delivery and immediately, placed in Hank's balanced salt solution (HBSS) at 0°C. Rat brains or portions of human fetal brain were minced and suspended in HBSS supplemented with 20 mM HEPES. The suspensions were allowed to settle and were washed 3 times in HBSS solution. They were then incubated at room temperature in 0.4 mg/ml trypsin (GIBCO) for 10 min. The supernatant was removed, and the sediment was resuspended in 2 ml of 0.25 mg/ ml DNase I and triturated 10 times gently with a Pasteur pipette. After 2 rain, the supernatant was gently removed and placed in a separate tube. This was repeated 2 times, and the pooled supernatants were centrifuged at 1000 rpm for 10 rain. The pellet of cells was resuspended in 5 ml of medium (Dulbecco's minimal essential medium [DMEM] , 10% fetal calf serum [Hyclone defined], 1 mM pyruvate, 2 mM glutamine, Pen-Strep-Amphotericin [Sigma, Hybrimax] ). The cells were plated on plastic dishes at 105 cells per milliter and grown until 50% confluent, with a medium change after 6 days.
Pure astrocytes were prepared by three different protocols. In the first, plated cells were incubated with 0.2 mg/ml trypsin for 15 rain. The supernatant, including nonadherent cells, was discarded. The remaining cells were then washed with HBSS and placed in fresh medium. The second is a standard procedure for obtaining pure astrocyte cultures, carried out according to Lee etal. (1992) . The subconfluent mixed glial cultures were placed in a rotary shaker at 180 rpm overnight. The supernatant and nonadherent cells were discarded, and the remaining cells were washed and supplemented with fresh medium. In the third protocol, cultures were treated with 5 mM H-Leu-O-Methyl ester for 18 hr according to Giulian (1987) , after which the adherent cells were washed and fresh medium added. In all three procedures, the cells remaining were >95% astrocytes as determined by morphology and GFAP staining. The number of microglia removed from (and therefore present in) the mixed glial cultures was assessed by staining with two macrophage/microglial cell-specific antisera, LN3 and Mac1 (ICN), and were found to be equal from all brain regions _+10%-15° .
One plate of mixed gila O r pure astrocytes was used in each experimental test. Complete medium was first replaced with serum-free N2 medium (high glucose DMEM, 2 mM glutamate, 100 U/ml strep-amp, 1 mM pyruvate, 5 ~g/ml insulin, 100 ~g/ml transferrin, 100 I~M putrescine, 30 nM selenium, 20 nM progesterone) for 2 hr. The cells were then exposed to the different treatments for 6 hr, except where noted. Following treatment, the cells were harvested and their RNA isolated for Northern blot analysis.
Northern Blot Analysis
Total cellular RNA was isolated as described by Chirgwin etal. (1979) . Briefly, cells (-10 mg of tissue) were washed with phosphate-buffered saline (PBS) and lysed directly on the culture plate in 1 ml of 4 M guanidinium isothiocyanate, 25 mM sodium citrate (pH 7), 0.5% sarcosyl, 0.1 M 2-mercaptoethanol. The cell lysate was layered on top of 2 ml of 5.7 M cesium chloride and centrifuged overnight at 39,000 x g. The RNA pellet obtained was resuspended in water, ethanol precipitated, resolubilized in water, and quantitated using spectrophotometry. Samples (3 #g) of RNA were denatured in 2.2 M formaldehyde, 50% formamide (v/v) and subjected to electrophoresis in a 1% agarose gel containing 2.2 M formaldehyde. The gels were stained with ethidium bromide and photographed to verify that each lane contained equal amounts of undegraded RNA. After transfer to nitrocellulose, the RNA was hybridized to 32P-labeled probe derived from either the hu man ACT cDNA or the rat ACT homolog, contrapsin, cDNA. Probes were labeled by priming with random hexamer oligonucleotides in the presence of [32P]dCTP (New England Nuclear). After hybridization, the membranes were washed under conditions of high stringency (0.1 x SSC, 55°C) and exposed to XAR-5 autoradiographic film (Kodak). Experiments were repeated at least 3 times with similar results.
Immunocytochemistry
Cells to be stained for GFAP or ACT were grown on poly-L-lysinecoated coverslips, fixed for 5 rain in 4% paraformaldehyde at room temperature, and then permeabilized with 0.1% Triton X-100 for 1 hr at room temperature. Coverslips with cells were then incubated with a 1:400 dilution of the primary antibody (mouse monoclonal anti-GFAP; Sigma) or rabbit polyclonal anti-ACT serum (Dako) at 4°C overnight. They were then washed 3 times for 5 min each with PBS. The cov-erslips were then incubated with the secondary antibody (goat antimouse tet='amethylrhodamine B isothiocyanate conjugate [1:500 dilution] or goat anti-rabbit fluorescein isothiocyanate conjugate [1:500 dilution]; Sigma) for 1 hr at room temperature, washed 3 times, and mounted on slides for visualization and photography.
Immunohistochemistry for IL-1 was performed as described by Griffin et al. (1989) . Briefly, paraffin-fixed sections from Alzheimer and control brain were processed on slides through three changes of xylenes and rehydrated by processing slides through 100%, 95%, and 75% ethanol. Sections were permeabilized in 0.05% Triton X-100 for 10 min, followed by 0.2 N HCI for 20 min. Endogeneous peroxidase was blocked by placing sections in 0.6% H2OJmethanol for 30 min. Blocking of sections was performed in 20% goat serum for 30 rain. The appropriate dilution of the primary antibody (1:20 for anti-human IL-1 ~; Cistron) or direct application of monoclonal antibody LN3 (ICN) was then applied to the sections overnight at 4°C. For the IL-1 ,z staining, a peroxidase-anti-peroxidase procedure was used. A 1:50 dilution of goat anti-rabbit IgG (Sigma) was applied to tissue sections for 30 min. A 1:300 dilution of rabbit peroxidase anti-peroxidase was then applied to the section for 30 min. Finally, the sections were developed with diaminobenzidine, counterstained with hematoxylin, dehydrated, and mounted with coverslips. For LN3 staining, the Vector ABC Vectastain kit was used for peroxidase staining, after which sections were counterstained with hematoxylin, dehydrated, and mounted with coverslips.
